Researchers analyzed the efficacy of rifaximin for relieving IBS-D symptoms, specifically abdominal pain, bloating, and bowel movement urgency. A 2-week course of rifaximin significantly improved ...
Please provide your email address to receive an email when new articles are posted on . Rifaximin retention decreased with time, with rates of 42% at 180 days dropping to 16% by 540 days. High cost, ...
LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fewer patients treated with rifaximin had an overt ...
Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy, a ...
Because patients with irritable bowel syndrome (IBS) can have alterations in bacterial bowel flora, antibiotic therapies have been proposed. To investigate whether antibiotic therapy is effective, ...
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy. HealthDay News — For patients with a history of overt hepatic ...
Nov. 2, 2005 (Honolulu) — Several gastrointestinal disorders beyond traveler's diarrhea respond to rifaximin (Xifaxan), according to investigators who presented their findings here at the 70th annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results